ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
93 hedge funds and large institutions have $888M invested in Adaptimmune Therapeutics in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
8% more funds holding
Funds holding: 86 → 93 (+7)
1.68% more ownership
Funds ownership: 9.88% → 11.57% (+1.7%)
50% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 36
Holders
93
Holding in Top 10
6
Calls
$10.3M
Puts
$2.56M
Top Buyers
| 1 | +$85.1M | |
| 2 | +$33.9M | |
| 3 | +$18M | |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$7.67M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$7.37M |
Top Sellers
| 1 | -$16M | |
| 2 | -$6.83M | |
| 3 | -$6.73M | |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$5.34M |
| 5 |
Renaissance Technologies
New York
|
-$3.64M |